Source comparison
CJC-1295 Research Comparison: DAC vs Non-DAC Forms
Half-Life 6–8 days (albumin-bound) <30 minutes (rapid enzymatic cleavage) DAC modification is the defining difference. Without it, the peptide requires multiple daily doses to maintain GH elevation. Dosing Frequency Once weekly or twice weekly 2–3× daily (befo
This comparison does not assign a generated winner or score.
- Half-Life
- 6–8 days (albumin-bound)
- <30 minutes (rapid enzymatic cleavage)
- DAC modification is the defining difference. Without it, the peptide requires multiple daily doses to maintain GH elevation.
- Dosing Frequency
- Once weekly or twice weekly
- 2–3× daily (before meals, pre-sleep)
- Non-DAC forms mimic natural pulsatility more closely but demand strict timing. DAC forms sacrifice some pulsatile fidelity for convenience.
- GH Pulse Pattern
- Sustained elevation of baseline pulses (amplitude ↑, frequency stable)
- Sharp, transient pulse 15–60 min post-dose, returns to baseline within 2–3 hours
- Non-DAC creates exaggerated single pulses; DAC amplifies the endogenous rhythm across days.
- IGF-1 Response Timeline
- Peak at 6–8 days, sustained 10–14 days
- Modest elevation (20–40%) within 24 hours if dosed 3× daily
- IGF-1 accumulation requires repeated GH exposure. Single-dose non-DAC won't move IGF-1 meaningfully.
- Receptor Desensitization Risk
- Low if dosed ≤2× weekly; moderate if dosed daily
- Minimal (short receptor occupancy per dose)
- DAC's extended half-life is an advantage and a risk. Overdosing suppresses pulsatility.
- Research Application
- Long-duration studies (4+ weeks), metabolic endpoints, IGF-1-dependent outcomes
- Acute GH dynamics, meal-timing studies, circadian rhythm research
- Choose based on your endpoint: DAC for sustained effects, non-DAC for discrete pulses.